Allergy Therapeutics plc (LON:AGY) will be posting its quarterly earnings results before the market opens on Monday, September 26th.

Allergy Therapeutics plc (LON:AGY) traded up 0.000% on Friday, reaching GBX 18.375. 1,348,738 shares of the company’s stock were exchanged. The firm has a 50 day moving average of GBX 18.79 and a 200 day moving average of GBX 22.72. Allergy Therapeutics plc has a 12 month low of GBX 18.00 and a 12 month high of GBX 34.82. The stock’s market capitalization is GBX 102.81 million.

A number of analysts have issued reports on AGY shares. Numis Securities Ltd started coverage on shares of Allergy Therapeutics plc in a research note on Wednesday. They issued a “buy” rating and a GBX 37 ($0.48) target price for the company. Panmure Gordon reiterated a “buy” rating and issued a GBX 53 ($0.69) target price on shares of Allergy Therapeutics plc in a research note on Thursday, July 14th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a GBX 72 ($0.94) target price on shares of Allergy Therapeutics plc in a research note on Friday, July 8th.

Allergy Therapeutics plc Company Profile

Allergy Therapeutics Plc is a United Kingdom-based pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum free products. It provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy.

Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.